Key Findings
Daiichi Sankyo and AstraZeneca announced that the combination therapy of Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate (ADC), and pertuzumab has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for approval as a first-line treatment for HER2-positive metastatic breast cancer in the EU. This favorable recommendation is based on the groundbreaking results from the DESTINY-Breast09 Phase III trial, which demonstrated a 44% reduction in the risk of disease progression or death and a median progression-free survival (PFS) exceeding three years compared to standard therapy.
Technical / Clinical Details
Enhertu is a HER2-directed DXd ADC that, upon binding to HER2 receptors on cancer cells, releases its potent DNA topoisomerase I inhibitor payload, DXd (deruxtecan), inside the cell, leading to cell cycle arrest and apoptosis. Pertuzumab, an antibody that inhibits HER2 dimerization, is believed to enhance the anti-tumor effect by more robustly blocking HER2 signaling when combined with Enhertu. The DESTINY-Breast09 trial was a large-scale, randomized Phase III study conducted in patients with previously untreated HER2-positive metastatic breast cancer. In this trial, the Enhertu plus pertuzumab combination arm showed a statistically and clinically significant improvement in PFS compared to standard HER2-targeted therapy (e.g., trastuzumab with a taxane-based regimen). A median PFS exceeding three years is particularly noteworthy, suggesting the potential to establish a new treatment paradigm for first-line HER2-positive metastatic breast cancer.
Background & Context
HER2-positive breast cancer accounts for approximately 15-20% of all breast cancers and is characterized by HER2 protein overexpression, which promotes cancer cell proliferation. While the prognosis for this type of cancer has improved with the advent of HER2-targeted agents, there remains a demand for further efficacy and survival benefits in the first-line treatment of metastatic disease. Enhertu has already received approval for various indications due to its high efficacy, but a recommendation for first-line treatment means its superior benefits can be offered to patients earlier, further elevating the standard of care for HER2-positive breast cancer. The collaboration between Daiichi Sankyo and AstraZeneca epitomizes the evolution of ADC technology and efforts to address unmet medical needs in cancer treatment.
Strategic Significance & Outlook
The CHMP’s recommendation is a crucial step towards final approval by the European Commission. If this combination therapy is approved in Europe, it will provide a powerful new treatment option for patients with HER2-positive metastatic breast cancer in the first-line setting. This is expected to extend patients’ progression-free survival and improve their quality of life. Future research will focus on long-term overall survival data for this combination therapy and further studies on its efficacy and safety in different patient populations. The evolution of ADC technology, centered on Enhertu, is anticipated to continue driving advancements in cancer treatment and contribute to the development of more effective and personalized therapies globally.
Source: https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260724_E.pdf
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments